A Prospective, Phase II Clinical Study of HIPEC Combined With NIPS and Tislelizumab Conversion Therapy for Gastric Cancer With Peritoneal Metastasis With Positive Cytology Alone or PCI Score ≤10

NCT07304258 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Gastric Cancer Peritoneal Metastases

Interventions

DEVICE: HIPEC
DEVICE: NIPS
DRUG: Paclitaxel Injection, S-1, tislelizumab

Sponsor

Hebei Medical University